This study will include women who will undergo pelvic reconstructive surgery and/or anti-incontinence sling procedures. Patients will be randomized to the combination of L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract in tablet or placebo twice a day during the seven days before and after surgery (total of 14 days). In this randomized, double-blind study, the investigators will assess treatment of clinically suspected or culture-proven urinary tract infections within 3 weeks of surgery (primary outcome), and risk factors for treatment for postoperative urinary tract infections (secondary outcomes) between the two study groups.

Inclusion Criteria:

• postoperative transurethral catheterization after surgery for pelvic organ prolapse and/or urinary incontinence
• patients aged ≥ 18 years

Exclusion Criteria:

• acute urinary tract infection at the moment of inclusion in the study
• antibiotic treatment prescribed for any other cause than urinary tract infection
• pregnancy
• known allergy to one of the elements of the active compound
• surgery for mesh excision
• surgery for urethral diverticulum
• surgery for fistula repair
• surgery for sacral neuromodulation
• any condition precluding the acquisition of written consent